Guidelines update, version 33.1 - Australian Living Evidence Collaboration

Updates to the Australian guidelines for the clinical care of people with COVID-19 this week include:

Additional study (Mohan et al.) added to the summary information for Ivermectin recommendation:

We have found five new studies comparing ivermectin with control (Ahmed et al. Int J Infect Dis doi: 10.1016/j.ijid.2020.11.191, Chaccour et al. Res Sq doi: 10.21203/rs.3.rs-116547/v1, Chachar et al. Int J Sciences doi: 10.18483/ijSci.2378, Kirti et al. medRxiv doi: 10.1101/2021.01.05.21249310 and Mohan et al. Res Sq doi: 10.21203/rs.3.rs-191648/v1). These studies are currently under review and an updated recommendation will be included in a future version of the guideline.

Additional remark added to the recommendation for Sarilumab:

The Taskforce notes the preprint of the adaptive, multicentre trial by Lescure et al., posted to medRxiv on 3 February, which randomised 420 patients with severe or critical COVID-19 to sarilumab (200 mg or 400 mg) or placebo. This study is currently under review and an updated recommendation will be included in a future version of the guideline.

Ends.

Topics

< Back to News

Featured

ALEC feedback form for new and updated pregnancy and/or postnatal care recommendations

27 June, 2024

The Australian Living Evidence Collaboration encourages everyone to visit the Australian Pregnancy Care Guidelines and the Australian Postnatal Care Guidelines to explore new and updated recommendations, and their...

Research Study: Using ‘living evidence’ in policy decisions

9 April, 2024

Continually updated, credible evidence syntheses, known as ‘living evidence syntheses’ can be valuable for healthdecisions, but we don’t yet know how to make them most useful for policy....

Tweets by evidence_aus